

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO. 9811-013-999	APPLICATION NO. 09/830,693
APPLICANT Shiau et al.	
FILED DATE 3/30/99 (§ 371 date, 01/29/02)	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
NE	AA International Search Report of PCT/US99/06937	10/07/99	PCT				
NE	AB EP 0 639 584 A1	6/21/94	EP				
NE	AC WO 92/00091	1/09/92	PCT				
NE	AD WO 93/06121	4/01/93	PCT				
NE	AE WO 94/28028	12/08/94	PCT				
NE	AF WO 97/21993	6/19/97	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

NE	AG	Adams et al., "Cross-validated maximum likelihood enhances crystallographic simulated annealing refinement", PNAS (1997) 94:5018-5023. <i>reference unreadable</i>
NE	AH	Anzick et al., "AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer", Science (1997) 277:965-968
NE	AI	Apriletti et al., "Expression of the rat $\alpha 1$ thyroid hormone receptor ligand binding domain in Escheria coli and the use of a ligand-induced conformation change as a method for its purification to homogeneity", Protein Expr. Purif., (1995) 6:363-370.
NE	AJ	Beato et al., "Steroid hormone receptors: many actors in search of a plot", Cell (1995) 83:851-857.
NE	AK	Berry et al., "Role of the two activating domains of the oestrogen receptor in the cell type and promoter context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen", the EMBO J. (1990) 9:2811-2818
NE	AL	Bourguet et al., "Crystal structure of the ligand-binding domain of the human nuclear receptor RXR- α ", Nature (1995) 375:377-382.
NE	AM	Brzozowski et al., "Molecular basis of agonism and antagonism in the oestrogen receptor", Nature (1997) 389:753-758.
NE	AN	Chang et al., "A thyroid hormone receptor coactivator negatively regulated by the retinoblastoma protein", PNAS (1997) 94:9040-9045.
NE	AO	Chen et al., "Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300", Cell (1997) 90:569-580.

NEued

11/16/04

AP	Cohen et al., "Molecular modeling software and methods for medicinal chemistry", J. Med. Chem. (1990) 33:883-894.
AQ	Collaborative Computational Project, Number 4 "The CCP4 Suite: Programs for Protein Crystallography", Acta Cryst. (1994) D50 760-763.
AR	Collingwood et al., "A natural transactivation mutation in the thyroid hormone β receptor: Impaired interaction with putative transcriptional mediators", PNAS (1997) 94:248-253.
AS	Danielian et al., "Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors", EMBO J. (1992) 11:1025-1033.
AT	Darimont et al., "Structure and specificity of nuclear receptor-coactivator interactions", Genes & Development (1998) 12:3343-3356.
AU	Desjarlais et al., "Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known three-dimensional structure", J. Med. Chem. (1988) 31:722-729.
AV	Ding et al., "Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities", Molecular Endocrinology (1998) 12:302-313.
AW	Douarin et al., "A possible involvement of TIF1 α and TIF1 β in the epigenetic control of transcription by nuclear receptors", (1996) 15:6701-6715. <i>EMBO J.</i>
AX	Eng et al., "Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics", Molecular and Cellular Biology (1997) 17:4644-4653.
AY	Esnouf et al., "An extensively modified version of MolScript that includes greatly enhanced coloring capabilities", Journal of Molecular Graphics and Modeling (1997), 15:132-134.
AZ	Farmer et al., "Drug design", Ariens, E.J. ed. (1980) 10:119-143. Academic Press NY.
BA	Feng et al., "Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors", Science (1998) 280:1747-1749.
BB	Furey et al., "'Phases' - A program package for the processing and analysis of diffraction data from macromolecules," Am. Cryst. Assoc. Mtg. Abstr. (1990) 18:73.
BC	Glass et al., "Nuclear receptor coactivators" Current Opinion in Cell Biology (1997) 9:222-232.
BD	Gradishar et al., "Clinical potential of new antiestrogens", (1997) 15:840-852
BE	Grainer et al., "Tamoxifen: Teaching an old drug new tricks?" Nature Medicine (1996) 2:381-385.
BF	Greene et al., "Purification of T47D human progesterone receptor and immunochemical characterization with monoclonal antibodies", Molecular Endocrinology (1988) 2:714-726.
BG	Greene et al., "Monoclonal antibodies to human estrogen receptor" PNAS (1980) 77:5115-5119
BH	Grese et al., "Molecular determinants of tissue selectivity in estrogen receptor modulators", PNAS (1997) 94:14105-14110.
BI	Hanstein et al., "p300 is a component of an estrogen receptor coactivator complex", PNAS (1996) 93:11540-11545.
BJ	Heery et al., "A signature motif in transcriptional co-activators mediates binding to nuclear receptors", Nature (1997) 387:733-736.
BK	Hegy et al., "Carboxymethylation of the human estrogen receptor ligand binding domain estradiol complex: HPLC/ESMS peptide mapping shows that cysteine 447 does not react with iodoacetic acid", Steroids (1996) 61:367-373.
BL	Henttu et al., "AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors", Molecular and Cellular Biology (1997) 17:1832-1839

NE	BM	Hong et al., "GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors", PNAS (1996) 93:4948-4952.
NE	BN	Hong et al., "GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors", Molecular and Cell Biology (1997) 17:2735-2744.
NE	BO	Horwitz et al., "Nuclear receptor coactivators and corepressors", Molecular Endocrinology (1996) 11:67-1177.
NE	BP	Huang et al., "Conic: A fast renderer for space filling molecules with shadows", J. Mol. Graphics, (1991) 9:230-242
NE	BQ	Janknecht et al., "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", PNAS (1991) 88:8972-8976.
NE	BR	Jordan et al., "Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and toloxifen in the immature rat uterus", Molecular and Cellular Endocrinology (1988) 58:291-306.
NE	BS	Jordan, Craig V., "Antiestrogenic action of raloxifene and tamoxifen", Journal of the National Cancer Institute (1998) 90:967-971.
NE	BT	Jurutka et al., "Mutations in the 1, 25-dihydroxyvitamin D ₃ receptor identifying C-terminal amino acids required for transcriptional activation that are functionally dissociated from hormone binding, heterodimeric DNA binding, and interaction with basal transcription factor IIB, in vitro." J. Biol. Chem. (1997) 272:14592-14599.
NE	BU	Kakizawa et al., "Ligand-dependent heterodimerization of thyroid hormone receptor and retinoid X receptor", J. Biol. Chem. (1997) 272:23799-23804..
NE	BV	Kalkhoven et al., "Isoforms of steroid receptor co-activator 2 differ in their ability to potentiate transcription by the oestrogen receptor", EMBO J. (1998) 17:232-243.
NE	BW	Kamei et al., "A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors", Cell (1996) 85:403-414.
NE	BX	Kato et al., "Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase", Science (1995) 270:1491-1494.
NE	BY	Kleywegt et al., "Halloween...masks and bones. In :From first map to final model", Council for the Central Laboratory of the Research Councils (1994) 59-66.
NE	BZ	Korach, Kenneth S., "Insights from the study of animals lacking functional estrogen receptor", Science (1994) 266:1524-1527.
NE	CA	Kuiper et al., "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β ", Endocrinology (1997) 138:863-870.
NE	CB	Kumar et al., "Functional domains of the human estrogen receptor", Cell (1987) 51:941-951.
NE	CC	Kuntz et al., "Structure-based strategies for drug design and discovery", Science (1992) 257:1078-1082.
NE	CD	Kussie et al., "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain", Science (1996) 274:948-953.
NE	CE	Landel et al., "The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins", The Endocrine Society (1994) 8:1407-1419. No reference
NE	CF	Landel et al., "Estrogen receptor accessory proteins augment receptor-DNA interaction and DNA bending", F. Steroid Biochem. Molec. Biol. (1997) 63:59-73.
NE	CG	Lazennec et al., "Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes", Molecular Endocrinology (1997) 11:1375-1386.
NE	CH	Lee et al., "Thyroid hormone receptor dimerization function maps to a conserved subregion of the ligand binding domain", Mol. Endocrinol. (1992) 6:1867-1873.

CI	Li et al., "RAC3 a steroid nuclear receptor associated coactivator that is related to SRC-1 and TIF2", PNAS (1997) 94:8479-8484.
CJ	Lin et al., "A conformation switch in nuclear hormone receptors is involved in coupling hormone binding to a corepressor release", Mol. Cell. Biol. (1997) 17:6131-6138.
CK	Masuyama et al., "Evidence for ligand dependent intramolecular folding of the AF-2 domain in vitamin D receptor activated transcription and coactivator interaction", Mol. Endocrinol. (1997) 11:1507-1515.
CL	Meng et al., "Automated docking with grid based energy evaluation", J. Computational Chem. (1992) 13:505-524.
CM	Merritt et al., "Raster 3D Version 2.0 A Program for Photorealistic Molecular Graphics", Acta Cryst. (1994) D50 869-873.
CN	Moras et al., "The nuclear receptor ligand binding domain: structure and function", Current Opin. Cell Biology (1998) 10:384-391.
CO	Mueller et al., "Complex heterocyclic structures a challenge for computer assisted molecular modeling" Bull. Soc. Chim. Belg. (1988) 97:655-667
CP	Murshudov et al., "Refinement of macromolecular structures by the maximum likelihood method", Acta Cryst (1997) D53 240-255.
CQ	Navia et al., "Use of structural information in drug design", Curr. Opin. Struct. Biol. (1992) 2:202-210.
CR	Noile et al., "Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor- γ " Nature (1998) 395:137-143.
CS	Norman et al., "The rat growth hormone gene contains multiple thyroid response elements", J. Biol. Chem. (1989) 264:12063-12073.
CT	Norris et al., "Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology", The Journal of Biological Chemistry (1998) 273:6679-6688.
CU	O'donnell et al., "Thyroid hormone receptor mutations that interfere with transcriptional activation also interfere with receptor interaction with a nuclear protein", Molecular Endocrinology (1991) 5:94-99.
CV	Onate et al., "Sequence and characterization of a coactivator for the steroid hormone receptor superfamily", Science (1995) 270:1354-1357.
CW	Otwinowski et al., "Processing of X-Ray diffraction data collected in oscillation mode", Methods in Enzymology (1997) 276:307-326.
CX	Radhakrishnan et al., "Solution structure of the KIX domain of the CBP bound to the transactivation domain of CREB: A model for activator Coactivator interactions", Cell (1997) 91:741-752.
CY	Renaud et al., "Crystal structure of the RAR- γ ligand-binding domain bound to all-trans retinoic acid", Nature (1995) 378:681-689.
CZ	Robertson et al., "Antiestrogen basicity-activity relationships: A comparison of the estrogen receptor binding and antutertrophic potencies of several analogues of (Z)-1,2-Diphenyl-1-[4[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, nolvadex) having altered basicity", J. Med. Chem. (1982) 25:167-171.
DA	Saatcioglu et al., "Mutations in the conserved C-terminal sequence in thyroid hormone receptor dissociate hormone-dependent activation from interference with AP1-activity", Mol. Cell. Biol. (1997) 17:4687-4695.
DB	Sadovsky et al., "Transcriptional activators differ in their responses to overexpression of the TATA-Box binding protein", Molecular and Cellular Biology (1995) 15:1554-1563.
DC	Seielstad et al., "Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis" Biochemistry (1995) 34:12605-12615.
DD	Seielstad et al., "Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli" Molecular Endocrinology, (1995) 9:647-658.

Noted 11/16/04


NE	DE	Shiau et al., "Activation of the human estrogen receptor by estrogenic and antiestrogenic compounds in <i>Saccharomyces cerevisiae</i> , a positive selection system", <i>Gene</i> (1996) 179:205-210.
NE	DF	Shiau et al., "The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by Tamoxifen", <i>Cell</i> (1998) 95:927-937.
NE	DG	Shibata et al., "Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action", <i>Recent Prog. Horm. Res.</i> (1997) 52:141-164.
NE	DH	Smigel et al., "Breast cancer prevention trial shows major benefit, some risk", <i>Journal of the National Cancer Institute</i> (1998) 90:647-648.
NE	DI	Smith et al., "Estrogen resistance caused by a mutation in the estrogen receptor gene in a man", <i>The New England Journal of Medicine</i> (1994) 331:1056-1061.
NE	DJ	Spencer et al., "Steroid receptor coactivator-1 is a histone acetyltransferase", <i>Nature</i> (1997) 389:194-198.
NE	DK	Tagami et al., "Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone", <i>Molecular and Cellular Biology</i> (1997) 17:2642-2648.
NE	DL	Takeshita et al., "Molecular cloning and properties of a full length putative thyroid hormone receptor coactivator", <i>Endocrinology</i> (1996) 137:3594-3597.
NE	DM	Tanenbaum et al., "Crystallographic comparison of the estrogen and progesterone receptors ligand binding domains", <i>PNAS</i> (1998) 95:5998-6003.
NE	DN	Tora et al., "The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties", <i>the EMBO J.</i> (1989) 8:1981-1986.
NE	DO	Torchia et al., "The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function", <i>Nature</i> (1997) 387:677-684.
NE	DP	Tsai et al., "Molecular mechanisms of action of steroid/thyroid receptor superfamily members", <i>Annu. Rev. Biochem.</i> (1994) 63:451-86.
NE	DQ	Uesugi et al., "Induced α -helix in the VP 16 activation domain upon binding to a human TAF" <i>Science</i> , (1996) 277:1310-1313.
NE	DR	Verlinde et al., "Structure-based drug design: Progress, results and challenges", <i>Structure</i> (1994) 2:577-587.
NE	DS	Voegel et al., "The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and independent pathways", <i>the EMBO J</i> (1998) 17:507-519.
NE	DT	Voegel et al., "TIF2 a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors", <i>the EMBO J</i> (1996) 15:3667-3675.
NE	DU	Wagner et al., "A structural role for hormone in the thyroid hormone receptor", <i>Nature</i> (1995) 378:690-697.
NE	DV	Wallace et al., "LIGPLOT: a program to generate schematic diagrams of protein ligand interactions", <i>Protein Engineering</i> (1995) 8:127-134.
NE	DW	Webb et al., "Tamoxifen activation of the estrogen receptor / AP-1 Pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens", <i>Molecular Endocrinology.</i> , (1995) 9:443-456.
NE	DX	White et al., "Ligand independent activation of the oestrogen receptor by mutation of a conserved tyrosine", <i>the EMBO J.</i> (1997) 16:1427-1435.
NE	DY	Whitefield et al., "A highly conserved region in the hormone binding domain of the human vitamin D receptor contains residues vital for heterodimerization with retinoid X receptor and for transcriptional activation", <i>Molecular Endocrinology</i> (1995) 9:1166-1179.
NE	DZ	Williams et al., "Atomic structure of progesterone complexed with its receptor", <i>Nature</i> (1998) 393:392-396.
NE	EA	Wrenn et al., "Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast", <i>The Journal of Biochemistry</i> (1993) 268:24089-24098.

N. Shred 11/16/09

NE	EB	Wurtz et al., "A canonical structure for the ligand-binding domain of nuclear receptors", Nature and Structural Biology (1996) 3:87-94
NE	DEC	Xu et al., "Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene", Science (1998) 279:1922-1925.
NE	DEC	Zhu et al., "The different hormone-dependent transcriptional activation of thyroid hormone receptor isoforms is mediated by interplay of their domains", J. Biol. Chem. (1997) 272:9048-9054.
NE	EE	(X-PLOR Resources) http://explor.csb.yale.edu/explor-info/ Last accessed on 11/16/98
NE	EF	Grasp Manual Page http://honiqlab.cpmc.columbia.edu/grasp/grasp_man.html Last accessed on 11/16/98
EXAMINER		DATE CONSIDERED
NE		11/16/98

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
JAN 31 2003
TECH CENTER 1609/2900



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

9811-013-999

APPLICATION NO

09/830,693

APPLICANT

Shiau, et al.

FILING DATE

3/30/99 (§ 371 date, 01/29/02)

GROUP

1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

JUL 21 2003

FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

NE	EG	Stephen E. Fawell, et al., "Characterization and Colocalization of Steroid Binding and Dimerization Activities in the Mouse Estrogen Receptor", Cell, Vol. 60, March 23, 1990, 953-962.
NE	EH	David F. V. Lewis, "Molecular Modelling of the Human Estrogen Receptor and Ligand Interactions Based on Site-directed Mutagenesis and Amino Acid Sequence Homology", J. Steroid Biochem. Molec. Biol., Vol. 52, No. 1, 1995, 55-65.
NE	EI	Lester F. Harris, et al., "Molecular Dynamics Simulation in Solvent of the Estrogen Receptor Protein DNA Binding Domain in Complex with a Non-Consensus Estrogen Response Element DNA Sequence", Journal of Biomolecular Structure & Dynamics, Vol. 15, Number 3, 1997, 407-430.
NE	EJ	George J. Maalouf, "Homology Model for the Ligand-Binding Domain of the Human Estrogen Receptor", Journal of Biomolecular Structure & Dynamics, Vol. 15, Number 5, 1998, 841-851.
NE	EK	John W. R. Schwabe, et al., "The Crystal Structure of the Estrogen Receptor DNA-Binding Domain Bound to DNA: How Receptors Discriminate between Their Response Elements", Cell, Vol. 75, November 5, 1993, 567-578.
NE	EL	John W. R. Schwabe, et al., "The oestrogen receptor recognizes an imperfectly palindromic response element through an alternative side-chain conformation", Structure, Vol. 3, 15 February, 1995, 201-213.
NE	EM	H. Ewa Witkowska, et al., "Characterization of bacterially expressed rat estrogen receptor β ligand binding domain by mass spectrometry: Structural comparison with estrogen receptor α ", Steroids, 1997, 62:621-631.
NE	EN	Jean-Marie Wurtz, et al., "Three-Dimensional Models of Estrogen Receptor Ligand Binding Domain Complexes, Based on Related Crystal Structures and Mutational Structure-Activity Relationship Data", J. Med. Chem., 1998, 41, 1803-1814.

EXAMINER

NEched

11/16/09

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

PTO-1449

Complete If Known

Application Number	09/830,693
Filing Date	January 29, 2002
First Named Inventor	Shiau, Andrew
Art Unit	1631
Examiner Name	Moran, Majorie A.
Attorney Docket Number	061040-0013-US

Sheet	1	of	1
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number Number - Kind Code ¹	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Translation	
						Yes	No
NE	WO 97/35195	09-25-1997	The Salk Institute for Biological Studies				

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
NE	RIBEIRO, R. C. J. et al., "Mechanisms of Thyroid Hormone Action: Insights from X-ray Crystallographic and Functional Studies", <i>Recent Progress in Hormone Research</i> , vol. 53, 1998, pages 351-384.
NE	SCHMIDT, S. et al., "Multiple Receptor Interaction Domains of GRIP1 Function in Synergy", <i>Nucleic Acids Research</i> , vol. 26, no. 5, 1998, pages 1191-1197.

Examiner Signature	<i>NE</i> <i>11/16/04</i>	Date Considered	
--------------------	---------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.